Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stake Lowered by Values First Advisors Inc.

Values First Advisors Inc. lessened its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 55.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,740 shares of the company’s stock after selling 21,179 shares during the period. Values First Advisors Inc.’s holdings in Mirum Pharmaceuticals were worth $494,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of MIRM. China Universal Asset Management Co. Ltd. lifted its position in Mirum Pharmaceuticals by 98.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock worth $31,000 after acquiring an additional 488 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Mirum Pharmaceuticals by 186.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,846 shares of the company’s stock worth $48,000 after purchasing an additional 1,202 shares during the period. Royal Bank of Canada increased its holdings in shares of Mirum Pharmaceuticals by 40.1% during the 2nd quarter. Royal Bank of Canada now owns 1,851 shares of the company’s stock worth $48,000 after purchasing an additional 530 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Mirum Pharmaceuticals during the 1st quarter worth about $49,000. Finally, Ameritas Investment Partners Inc. increased its holdings in shares of Mirum Pharmaceuticals by 85.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,208 shares of the company’s stock worth $57,000 after purchasing an additional 1,016 shares during the period.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock remained flat at $25.12 during trading hours on Thursday. 424,360 shares of the company’s stock traded hands, compared to its average volume of 597,991. The company has a quick ratio of 4.19, a current ratio of 4.45 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $1.18 billion, a PE ratio of -6.34 and a beta of 1.16. Mirum Pharmaceuticals, Inc. has a 1 year low of $21.83 and a 1 year high of $35.56. The stock has a 50 day moving average of $27.46 and a 200-day moving average of $29.20.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. The company had revenue of $69.55 million for the quarter, compared to analyst estimates of $66.73 million. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on MIRM shares. JMP Securities boosted their price objective on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, March 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $35.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, February 29th. HC Wainwright upped their target price on shares of Mirum Pharmaceuticals from $45.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, March 14th. SVB Leerink lowered their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. Finally, Raymond James lowered their target price on shares of Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, December 19th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $52.11.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt acquired 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were acquired at an average cost of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at approximately $347,200. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Mirum Pharmaceuticals news, COO Peter Radovich sold 1,408 shares of the stock in a transaction on Monday, January 8th. The shares were sold at an average price of $28.03, for a total value of $39,466.24. Following the sale, the chief operating officer now directly owns 36,485 shares in the company, valued at $1,022,674.55. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Eric Bjerkholt bought 2,000 shares of the business’s stock in a transaction on Wednesday, March 27th. The stock was purchased at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the acquisition, the chief financial officer now owns 14,000 shares of the company’s stock, valued at approximately $347,200. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 13,202 shares of company stock worth $359,119. Corporate insiders own 24.06% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.